Daiichi Sankyo lets warrant conversion option in Ranbaxy lapse
This article was originally published in Scrip
Executive Summary
Japan's Daiichi Sankyo, which holds a 64% stake in Ranbaxy Laboratories, has not exercised an option to convert warrants into equity shares in the Indian generics firm.